Population, Policy and Practice Research and Teaching Department, UCL GOS Institute of Child Health, London, UK; Ulverscroft Vision Research Group, UCL GOS Institute of Child Health, London, UK.
Population, Policy and Practice Research and Teaching Department, UCL GOS Institute of Child Health, London, UK; Ulverscroft Vision Research Group, UCL GOS Institute of Child Health, London, UK; Great Ormond Street Hospital for Children NHS Trust, London, UK; National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital and UCL GOS ICH, London, UK; National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.
Lancet Child Adolesc Health. 2021 Mar;5(3):190-200. doi: 10.1016/S2352-4642(20)30366-7. Epub 2021 Jan 29.
The WHO VISION 2020 global initiative against blindness, launched in 2000, prioritised childhood visual disability by aiming to end avoidable childhood blindness by 2020. However, progress has been hampered by the global paucity of epidemiological data concerning childhood visual disability. The British Childhood Visual Impairment and Blindness Study 2 (BCVIS2) was done to address this evidence gap.
BCVIS2 was a prospective UK-wide, cross-sectional, observational study to establish an inception cohort of children newly diagnosed with visual impairment. Opthalmologists and paediatricians reported cases from 89 hospitals and community centres across the UK. We included children aged 18 years or younger who were newly diagnosed with any condition causing impaired visual acuity to a level of 0·5 logMAR or worse (worse than 6/18 Snellen) in each eye, or equivalent vision as assessed by standard qualitative measures, between Oct 1, 2015, and Nov 1, 2016. Eligible children were notified simultaneously but independently by their managing ophthalmologists and paediatricians via the two national active surveillance schemes, the British Ophthalmological Surveillance Unit and the British Paediatric Surveillance Unit. Standardised detailed demographic, socioeconomic, and clinical data about detection, management, and treatment were collected at diagnosis and 1 year later. We calculated incidence estimates and relative rates by key sociodemographic factors. We did descriptive analyses of underlying ophthalmic disorders and non-ophthalmic comorbidities.
61 (7%) of 845 eligible children initially notified were ineligible at follow-up because of improved vision after treatment. Thus, the study sample comprised 784 children with permanent newly-diagnosed all-cause visual impairment, severe visual impairment, or blindness. 559 (72%) of 778 children had clinically significant non-ophthalmic impairments or conditions. 28 (4%) of 784 children died within a year after diagnosis of visual disability (all had underlying systemic disorders). Incidence of visual disability in the first year of life was 5·19 per 10 000 children (95% CI 4·71-5·72), almost ten times higher than among 1-to-4-year-olds and between 20 times and 100 times higher than in the older age groups. The overall cumulative incidence (or lifetime risk) of visual impairment, severe visual impairment, or blindness was 10·03 per 10 000 children (9·35-10·76). Incidence rates were higher for those from any ethnic minority group, the lowest quintile of socioeconomic status, and those born preterm or with low birthweight. 345 (44%) of 784 children had a single affected anatomical site. Disorders of the brain and visual pathways affected 378 (48%) of 784 children.
BCVIS2 provides a contemporary snapshot of the heterogeneity, multi-morbidity, and vulnerability associated with childhood visual disability in a high-income country. These findings could facilitate developing and delivering health care and planning of interventional research. Our findings highlight the importance of including childhood visual disability as a sentinel event and metric in global child health initiatives.
Fight for Sight, National Institute for Health Research, and Ulverscroft Foundation.
世界卫生组织(WHO)于 2000 年发起的“视觉 2020 全球倡议”旨在消除可避免的儿童盲症,目标是在 2020 年年底前结束儿童失明。然而,由于全球缺乏有关儿童视觉障碍的流行病学数据,该倡议的进展受到了阻碍。英国儿童视觉障碍和盲症研究 2 期(BCVIS2)旨在填补这一证据空白。
BCVIS2 是一项前瞻性的英国全国性、横断面、观察性研究,旨在建立一个新诊断为视觉障碍的儿童队列。眼科医生和儿科医生从英国 89 家医院和社区中心报告病例。我们纳入了在 2015 年 10 月 1 日至 2016 年 11 月 1 日期间,新诊断为任何导致双眼视力低于 0.5 对数视力( worse than 6/18 Snellen)或等效视力(由标准定性测量评估)的儿童,年龄为 18 岁以下。符合条件的儿童通过两个全国性主动监测计划(英国眼科监测单位和英国儿科监测单位)同时但独立地由他们的管理眼科医生和儿科医生通知。在诊断时和 1 年后收集了关于检测、管理和治疗的详细人口统计学、社会经济和临床数据。我们按关键社会人口因素计算了发病率估计值和相对比率。我们对潜在的眼科疾病和非眼科合并症进行了描述性分析。
在最初通知的 845 名符合条件的儿童中,有 61 名(7%)在随访时因治疗后视力改善而不符合条件。因此,研究样本包括 784 名患有永久性新诊断的全因视力障碍、重度视力障碍或失明的儿童。778 名儿童中有 559 名(72%)存在有临床意义的非眼科损伤或疾病。在诊断为视力障碍后的一年内,有 28 名(4%)儿童死亡(均患有潜在的系统性疾病)。1 岁以下儿童的视觉障碍发病率为每 10000 名儿童 5.19 例(95%CI 4.71-5.72),几乎是 1-4 岁儿童的 10 倍,是年龄较大组的 20 倍至 100 倍。视觉障碍、重度视觉障碍或失明的总累积发病率(或终生风险)为每 10000 名儿童 10.03 例(9.35-10.76)。来自任何少数民族群体、社会经济地位最低五分位数和早产或低出生体重的儿童发病率较高。784 名儿童中有 345 名(44%)有单一受累解剖部位。784 名儿童中有 378 名(48%)存在大脑和视觉通路疾病。
BCVIS2 提供了一个高收入国家儿童视觉障碍的异质性、多合并症和脆弱性的现代图片。这些发现可以促进医疗保健的制定和提供,并为干预性研究的规划提供便利。我们的研究结果强调了将儿童视觉障碍作为全球儿童健康倡议中的一个重要事件和指标的重要性。
视力之战、英国国家卫生研究院和乌尔弗斯克罗夫特基金会。